iPSCs in Neurodegenerative Disorders: A Unique Platform for Clinical Research and Personalized Medicine

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985904%3A_____%2F22%3A00561885" target="_blank" >RIV/67985904:_____/22:00561885 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00669806:_____/22:10446929 RIV/00216208:11140/22:10446929 RIV/00216224:14310/22:00128903

Výsledek na webu

<a href="https://www.mdpi.com/2075-4426/12/9/1485" target="_blank" >https://www.mdpi.com/2075-4426/12/9/1485</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/jpm12091485" target="_blank" >10.3390/jpm12091485</a>

Jazyk výsledku

angličtina

Název v původním jazyce

iPSCs in Neurodegenerative Disorders: A Unique Platform for Clinical Research and Personalized Medicine

Popis výsledku v původním jazyce

In the past, several animal disease models were developed to study the molecular mechanism of neurological diseases and discover new therapies, but the lack of equivalent animal models has minimized the success rate. A number of critical issues remain unresolved, such as high costs for developing animal models, ethical issues, and lack of resemblance with human disease. Due to poor initial screening and assessment of the molecules, more than 90% of drugs fail during the final step of the human clinical trial. To overcome these limitations, a new approach has been developed based on induced pluripotent stem cells (iPSCs). The discovery of iPSCs has provided a new roadmap for clinical translation research and regeneration therapy. In this article, we discuss the potential role of patient-derived iPSCs in neurological diseases and their contribution to scientific and clinical research for developing disease models and for developing a roadmap for future medicine. The contribution of humaniPSCs in the most common neurodegenerative diseases (e.g., Parkinson's disease and Alzheimer's disease, diabetic neuropathy, stroke, and spinal cord injury) were examined and ranked as per their published literature on PUBMED. We have observed that Parkinson's disease scored highest, followed by Alzheimer's disease. Furthermore, we also explored recent advancements in the field of personalized medicine, such as the patient-on-a-chip concept, where iPSCs can be grown on 3D matrices inside microfluidic devices to create an in vitro disease model for personalized medicine.

Název v anglickém jazyce

iPSCs in Neurodegenerative Disorders: A Unique Platform for Clinical Research and Personalized Medicine

Popis výsledku anglicky

In the past, several animal disease models were developed to study the molecular mechanism of neurological diseases and discover new therapies, but the lack of equivalent animal models has minimized the success rate. A number of critical issues remain unresolved, such as high costs for developing animal models, ethical issues, and lack of resemblance with human disease. Due to poor initial screening and assessment of the molecules, more than 90% of drugs fail during the final step of the human clinical trial. To overcome these limitations, a new approach has been developed based on induced pluripotent stem cells (iPSCs). The discovery of iPSCs has provided a new roadmap for clinical translation research and regeneration therapy. In this article, we discuss the potential role of patient-derived iPSCs in neurological diseases and their contribution to scientific and clinical research for developing disease models and for developing a roadmap for future medicine. The contribution of humaniPSCs in the most common neurodegenerative diseases (e.g., Parkinson's disease and Alzheimer's disease, diabetic neuropathy, stroke, and spinal cord injury) were examined and ranked as per their published literature on PUBMED. We have observed that Parkinson's disease scored highest, followed by Alzheimer's disease. Furthermore, we also explored recent advancements in the field of personalized medicine, such as the patient-on-a-chip concept, where iPSCs can be grown on 3D matrices inside microfluidic devices to create an in vitro disease model for personalized medicine.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

<a href="/cs/project/NU20-09-00437" target="_blank" >NU20-09-00437: Identifikace změn glutamátergních drah specifických pro sporadickou formu Alzheimerovy choroby v lidských neuronech a astrocytech indukovaných z buněk pacientů</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Personalized Medicine

ISSN

2075-4426

e-ISSN

2075-4426

Svazek periodika

12

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

18

Strana od-do

1485

Kód UT WoS článku

000857061800001

EID výsledku v databázi Scopus

2-s2.0-85138617022